Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on course for regulatory filings later this year. The readout from the TRIUMPH-1 ...

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a ...

There is only one approved therapy for lung disease non-cystic fibrosis bronchiectasis (NCFB) in the US and Europe – Insmed's ...

The Singapore Court of Appeal has retained an injunction against KBP Bio and its founder, Dr Huang Zhenhua, and ruled that a lawsuit brought by Novo Nordisk will be taken to arbitration. Last year, ...

A 'hybrid' therapy for Parkinson's disease developed by Remepy, combining a drug with a digital therapeutic, has shown ...

UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category with $21 billion ...

The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola that is causing ...

A report that the NHS is considering scaling back its recruitment drive and deploying greater use of AI to plug the gap has ...

Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3 billion, Parabilis Medicines has decided to ...

A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...

Underlying many of these challenges is a broader industry mindset that can, at times, slow progress. There is often a ...